{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-142297","form_type":"8-K","ticker":"CERS","cik":"0001020214","company_name":"CERUS CORP","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.342788+00:00","generated_at":"2026-06-25T23:15:55.121681+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cerus Q1 total revenue $43.0M (+46% YoY); raises FY product revenue guidance to $160-165M","bullets":["Product revenue $37.4M (+60% YoY) driven by INTERCEPT platelet kit sales in the U.S.","Net loss improved to $12.3M ($0.07/shr) vs $17.5M ($0.10/shr) a year ago.","Non-GAAP Adjusted EBITDA improved to -$3.7M from -$11.5M year-over-year.","Signed multi-year INTERCEPT platelet contract with American Red Cross and 10-year Fresenius Kabi manufacturing extension.","Cash and investments $108.6M at March 31, 2022; net cash used in operations $21.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-142297","json":"https://secwatch.observer/filing/0001193125-22-142297.json","markdown":"https://secwatch.observer/filing/0001193125-22-142297.md","text":"https://secwatch.observer/filing/0001193125-22-142297.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1020214/000119312522142297/0001193125-22-142297-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1020214/000119312522142297/d667280d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:15:55.121681+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}